OFS Capital Corp current report, 05 October 2026

OFS Capital Corporation — Form 8-K Summary

Event date: October 5, 2026; the report was signed October 6, 2026. This is an event filing, not a quarterly or annual results report.

Business context and transaction

OFS SBIC I, LP, a wholly owned subsidiary, admitted a third-party limited partner that acquired 56.62% of the partnership interests. The investor paid $52,279,500 to SBIC I LP, and the full amount was distributed to OFS Capital. OFS Capital’s wholly owned subsidiary remains the general partner and retains sole and exclusive authority to manage and control SBIC I LP.

Key financial and investment information

  • SBIC I LP holds 400 Class A shares of Pfanstiehl Holdings, Inc., a manufacturer of high-purity pharmaceutical ingredients.
  • As of June 30, 2026, that holding represented approximately 84.0% of OFS Capital’s net assets and 31.8% of its total investments at fair value.
  • OFS Capital plans to use transaction proceeds, net of fees, expenses, and other transaction costs, for debt and equity investments consistent with its investment objectives and for general corporate purposes.
  • The filing provides no transaction-cost amount or updated revenue, earnings, cash flow, margin, debt, or liquidity figures.

Changes, outlook, and risks

The transaction changes the limited-partner ownership of SBIC I LP, while OFS Capital retains control through its general partner. The filing does not quantify the resulting change in OFS Capital’s economic interest or provide a specific investment timetable. The intended use of proceeds is forward-looking and subject to risks described in the company’s filings, including its 2025 Form 10-K; actual results may differ, and the company disclaims an obligation to update forward-looking statements.

Investor items to verify

  • Net proceeds after fees, expenses, and transaction-related costs.
  • The effect of the transferred partnership interest on OFS Capital’s economic exposure to SBIC I LP and Pfanstiehl Holdings.
  • Whether and how proceeds are deployed, and the resulting portfolio and liquidity effects.
  • Any subsequent changes to the Pfanstiehl investment’s valuation or its concentration in OFS Capital’s net assets.